Moximed marked the first commercial cases with MISHA, an implantable shock absorber for the knee.
The FDA-cleared MISHA Knee is indicated to treat people with medial knee osteoarthritis (OA) who failed to find relief from non-surgical or surgical treatment, continue to experience pain that interferes with daily activities, and are ineligible for or unwilling to undergo joint replacement due to age or absence of advanced OA.
“We’ve had unsolicited online requests for access to the MISHA Knee System from over one hundred surgeons across the U.S., and we receive several online patient inquiries every day,” said Anton Clifford, Ph.D., founder and CEO of Moximed. “Despite this broad enthusiasm, our roll out plan remains focused on delivering high quality education to our surgeon users, and I’m delighted to see our first surgeons represent both top-tier academic centers and high-caliber private practices.”
Moximed marked the first commercial cases with MISHA, an implantable shock absorber for the knee.
The FDA-cleared MISHA Knee is indicated to treat people with medial knee osteoarthritis (OA) who failed to find relief from non-surgical or surgical treatment, continue to experience pain that interferes with daily activities, and are...
Moximed marked the first commercial cases with MISHA, an implantable shock absorber for the knee.
The FDA-cleared MISHA Knee is indicated to treat people with medial knee osteoarthritis (OA) who failed to find relief from non-surgical or surgical treatment, continue to experience pain that interferes with daily activities, and are ineligible for or unwilling to undergo joint replacement due to age or absence of advanced OA.
“We’ve had unsolicited online requests for access to the MISHA Knee System from over one hundred surgeons across the U.S., and we receive several online patient inquiries every day,” said Anton Clifford, Ph.D., founder and CEO of Moximed. “Despite this broad enthusiasm, our roll out plan remains focused on delivering high quality education to our surgeon users, and I’m delighted to see our first surgeons represent both top-tier academic centers and high-caliber private practices.”
Copy to clipboard 
